Utilising an interleukin-12 plasmid: a novel COVID-19 vaccine
Dr Bernard Fox from Providence Cancer Institute explains how OncoSec’s CORVax12 vaccine works to potentially combat COVID-19.
List view / Grid view
Articles
Begin with the end in mind: designing synthetic antibiotics with a universal mechanism of action
James Graham from Recce Pharmaceuticals discusses how a new class of synthetic antibiotics could be the key to preventing the spread of antibiotic resistance.
Intravenous immunoglobulins, hyperimmunes and pandemic viruses
David Johnson of GigaGen discusses how recombinant forms of intravenous immunoglobulins (IVIG) could overtake current IVIG therapies and be used in the treatment of COVID-19.
Developing respiratory therapeutics for prophylaxis and treatment
Drug Target Review explores antiviral Fc-conjugates and how they could be used as a COVID-19 prophylactic and therapeutic with Dr Jeff Stein, Cidara’s President and CEO.
Cytokine storms: a major killer in patients with severe COVID-19 infection
Professor Saad Shakir explains why cytokine storms occur in COVID-19 patients and suggests potential therapies for the symptoms of the coronavirus.
Natural peptides versus COVID-19
Peptides could serve as a potential platform for development of novel drugs for the treatment of the COVID-19 coronavirus.
Histone deacetylase 2 (HDAC2) regulates pathological response of inflammatory monocytes: a potential target of adjuvant therapies for COVID-19 infection
Histone deacetylase 2 (HDAC2) plays a key role in the regulation of inflammatory response in monocytes so could be a target for COVID-19, argue Dr Rosa Maria Tordera and Maria Cortes.
Developing immunotherapies for hard-to-treat cancers
Exploring how therapies with multi-faceted approaches could improve options for treatment-refractory cancers, like pancreatic and triple-negative breast cancer.
High-throughput screening for antibody-based drugs
A collaboration between academia and industry has produced an assay and new screening technique which utilises directed evolution for the discovery of antibody-based drugs.
The coronavirus as a personalised enemy of mankind
How has evolution led us to the point where humans are an ideal host for SARS-CoV-2, the virus that causes the COVID-19 coronavirus?
Mesenchymal stem cells secretome as a prospective therapeutic option for COVID-19 patients
Researchers propose using mesenchymal stem cells to counter the pro-inflammatory cytokines associated with COVID-19 coronavirus symptoms.
Refreshing how we approach neuroscience with a novel screening technology
Drug Target Review discusses how NETSseq, a novel profiling technology, is bringing new insights to neurodegenerative and psychiatric diseases.
Gender-specific coronavirus infections in the light of evolution
Dr Kutschera discusses the differences between males and females in relation to infection from the COVID-19 coronavirus.
COVID-19 and big pharma: what are 15 leading companies doing to develop a coronavirus vaccine?
A new report has revealed the vaccine R&D efforts of 15 of the leading pharmaceutical companies to combat the COVID-19 coronavirus.
Predicting which diabetes treatments will reach clinical trials
Researchers at MIT have developed a mathematical model that can calculate whether diabetes treatments in pre-clinical trials will be successful in humans.